Brazil Tuesday suspended its deal with Bharat Biotech for 20 million Covaxin doses amid an ongoing investigation into alleged irregularities & corruption. ThePrint gives you the details.
Interim results from the phase 3 trial indicate that Covaxin has 78% efficacy against symptomatic disease & 100% efficacy against severe Covid, including hospitalisation, NIH said.
Subject Expert Committee, which advises DCGI on approvals for new drugs & vaccines. has not yet discussed changing the status of Covaxin from emergency use to full licensure.
Bharat Biotech submitted phase 3 trial data of Covaxin to the Drug Controller General of India. The data is crucial to ascertaining the efficacy of a vaccine.
A pre-submission meeting with WHO will take June 23 during which the vaccine maker will have an opportunity to submit a summary on the overall quality of the jab.
Bharat Biotech said reasons such as low procurement volumes, high distribution costs and retail margins among others contribute to the higher pricing of Covaxin.
The Drugs Controller General of India had granted permission for conducting the phase 2/3 clinical trial of Bharat Biotech's Covaxin among children aged two to 18 years on 12 May.
The IndiGo crisis is nothing short of a threat to India’s stability. Could it be an experiment? Can this happen in any other crucial sector like power or railways?
RBI Handbook of Statistics shows state’s GSDP has more than doubled in past decade, finishing second behind Maharashtra. It has performed well across health & education parameters as well.
It is argued that India-Israel ties are moving from buyer–seller dynamic to one focused on joint development & manufacturing partnership, a shift 'more durable' than traditional arms sales.
Don’t blame misfortune. This is colossal incompetence and insensitivity. So bad, heads would have rolled even in the old PSU-era Indian Airlines and Air India.
COMMENTS